Asset Management Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Asset Management Group’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,472	Closed	-$24K	–	104
2017 Q2	$24K	Hold	2,472	–	–	0.01%	104
2017 Q1	$60K	Hold	2,472	–	–	0.02%	102
2016 Q4	$79K	Hold	2,472	–	–	0.03%	101
2016 Q3	$124K	Hold	2,472	–	–	0.05%	101
2016 Q2	$105K	Hold	2,472	–	–	0.05%	98
2016 Q1	$163K	Hold	2,472	–	–	0.07%	99
2015 Q4	$154K	Hold	2,472	–	–	0.07%	99
2015 Q3	$166K	Hold	2,472	–	–	0.08%	96
2015 Q2	$241K	Hold	2,472	–	–	0.11%	91
2015 Q1	$231K	Sell	2,472 -1,271	-34%	-$108K	0.11%	89
2014 Q4	$333K	Hold	3,743	–	–	0.17%	76
2014 Q3	$259K	Hold	3,743	–	–	0.14%	77
2014 Q2	$215K	Hold	3,743	–	–	0.12%	78
2014 Q1	$148K	Hold	3,743	–	–	0.09%	79
2013 Q4	$157K	Hold	3,743	–	–	0.1%	77
2013 Q3	$112K	Hold	3,743	–	–	0.07%	72
2013 Q2	$199K	Buy	+3,743	New	+$164K	0.14%	70

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Asset Management Group's MACK Position: Q3 2017 in Review

Asset Management Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 2,472 shares — an estimated $24K sold.

Asset Management Group first reported a position in MACK in Q2 2013 and held it in 17 quarters. The position peaked at $333K in Q4 2014. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Asset Management Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Asset Management Group sold 2,472 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $24K.
Asset Management Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
Asset Management Group's Merrimack Pharmaceuticals, Inc. position peaked at $333K in Q4 2014.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Asset Management Group's 13F filing for Q3 2017, filed 14 Nov 2017.